Bloomberg "Anywhere" Remote Login Bloomberg "Terminal" Request a Demo

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $0.46 USD
Change Today +0.02 / 4.58%
Volume 92.4K
OPXA On Other Exchanges
Symbol
Exchange
NASDAQ CM
Berlin
As of 11:05 AM 09/3/15 All times are local (Market data is delayed by at least 15 minutes).

opexa therapeutics inc (OPXA) Snapshot

Open
$0.46
Previous Close
$0.44
Day High
$0.47
Day Low
$0.44
52 Week High
09/3/14 - $1.36
52 Week Low
08/24/15 - $0.30
Market Cap
24.4M
Average Volume 10 Days
546.4K
EPS TTM
$-0.43
Shares Outstanding
53.4M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for OPEXA THERAPEUTICS INC (OPXA)

Related News

No related news articles were found.

opexa therapeutics inc (OPXA) Related Businessweek News

No Related Businessweek News Found

opexa therapeutics inc (OPXA) Details

Opexa Therapeutics, Inc., a biopharmaceutical company, develops personalized immunotherapy to treat multiple sclerosis (MS) and other autoimmune diseases, such as neuromyelitis optica (NMO) based on its proprietary T-cell technology. The company’s product candidate is Tcelna, a novel T-cell immunotherapy, which is in Phase IIb clinical development for the treatment of patients with secondary progressive MS. It is also developing OPX-212 as an autologous T-cell immunotherapy for the treatment of NMO. The company was formerly known as PharmaFrontiers Corp. and changed its name to Opexa Therapeutics, Inc. in June 2006. Opexa Therapeutics was founded in 2003 and is based in The Woodlands, Texas.

39 Employees
Last Reported Date: 02/23/15
Founded in 2003

opexa therapeutics inc (OPXA) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $579.2K
Chief Financial Officer and Chief Accounting ...
Total Annual Compensation: $317.0K
Chief Development Officer
Total Annual Compensation: $318.1K
Compensation as of Fiscal Year 2014.

opexa therapeutics inc (OPXA) Key Developments

Opexa Therapeutics, Inc. Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2015

Opexa Therapeutics, Inc. reported unaudited consolidated earnings results for the second quarter and six months ended June 30, 2015. For the quarter, the company reported option revenue of $726,292 compared to $307,686 a year ago. Net loss was $3,496,881, or $0.07 loss per basic and diluted share compared with a $4,163,259 or $0.37 per basic and diluted share a year ago. Operating loss was $3,509,192 compared to $4,167,549 a year ago. The decreased net loss for the quarter is primarily related to the increase in revenue due to the March 2015 amendment to their Option and License Agreement with Merck Serono and a decrease in research and development expenses, which was partially offset by the increase in general and administrative expenses. For the six months, the company reported option revenue of $1,103,745 compared to $656,523 for the same period last year. Net loss was $6,847,761 or $0.18 per basic and diluted share compared to $7,818,833 or $0.28 per basic and diluted share for the same period last year. Operating loss was $6,871,850 compared to $7,828,317 a year ago.

Opexa Therapeutics, Inc. to Report Q2, 2015 Results on Aug 12, 2015

Opexa Therapeutics, Inc. announced that they will report Q2, 2015 results at 8:01 PM, GMT Standard Time on Aug 12, 2015

Opexa Therapeutics, Inc., Q2 2015 Earnings Call, Aug 12, 2015

Opexa Therapeutics, Inc., Q2 2015 Earnings Call, Aug 12, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
OPXA:US $0.46 USD +0.02

OPXA Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Caladrius Biosciences Inc $1.73 USD +0.0899
China Pharma Holdings Inc $0.23 USD 0.00
Sinovac Biotech Ltd $5.41 USD +0.03
StemCells Inc $0.50 USD +0.0305
Tianyin Pharmaceutical Co Inc $0.27 USD 0.0001
View Industry Companies
 

Industry Analysis

OPXA

Industry Average

Valuation OPXA Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 12.9x
Price/Book 1.8x
Price/Cash Flow NM Not Meaningful
TEV/Sales 3.2x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact OPEXA THERAPEUTICS INC, please visit www.opexatherapeutics.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.